Events

Anti-Counterfeiting Pharma

Date/Time
Date(s) - 07 Mar 17 - 08 Mar 17
All Day

Location
TBC
TBC
London


United Kingdom

Organizers
Recunnect

Map Unavailable

3rd Anti-Counterfeiting Pharma Conference 2017: While the pharmaceutical industry has to constantly evolve tech and research to fight the new challenges in the health care sector on the one hand, it is kept on its toes due to the rampant counterfeit products on the other. Designed in the guise as genuine, these spurious products often lead to adverse reactions or lack of effective healing properties, diminishing confidence in medicines in general and healthcare providers/health systems in particular.
As per the 2016 International Trade Administration Top Market Reports on Pharmaceuticals, estimates on the size of the global Fake Drugs market range from $75 to $200 billion and can make up half of all drugs sold in some low-income countries.

The World Health Organisation (WHO) estimates that up to 30 per cent of branded drugs sold in developing nations are counterfeit which can have profound implications for both patients and the brand.

Wielding a double edged sword, counterfeit products pose a peril to pioneering and generic industries as well as raise the price of the genuine products by diverting the R&D corpus towards devising stricter methods to control counterfeiting.

Visit the event website http://www.recunnect.com/events/pharma-events/3rd-anti-counterfeiting-pharma-2017/

PCI Pharma Services will be exhibiting at this event on 7th to 8th March 2017

Leave a Reply

Your email address will not be published. Required fields are marked *

3 × three =

Explore the PCI Process Phase by Phase

PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL

Swipe to explore the PCI Process

PRE CLINICAL

pre-clinical-icon
  • Formulation Development
  • Analytical development/characterisation

PHASE 1

PCI Phase 1
  • Formulation Development
  • Analytical Development
  • Drug in capsule/vial technology (Xcelodose)®
  • Phase I product manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase I packaging and labelling
  • Storage and distribution

PHASE 2

PCI Phase 2
  • Formulation Optimization
  • Dosage Form Process Validation
  • Analytical Testing and Stability Services
  • Phase II Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase II packaging and labelling
  • Storage and distribution

PHASE 3

PCI Phase 3
  • Comparator Sourcing
  • Scale Up Studies
  • Phase III Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase III packaging and labelling
  • Analytical testing and stability services
  • Storage and distribution

COMMERCIAL

PCI Commercial Phase
  • Scale up for commercial supply
  • Commercial product manufacture
  • Commercial packaging and labelling
  • Validation services
  • Analytical testing and stability services
  • Product release to market
  • Storage and distribution

PCI Points...

You told us what aspects you value as "very important" when choosing a vendor...

Why choose us...

Our global reach and localized support ensures PCI as a strategic partner remains focussed on delivering speed-to-market and the commercial success of our customers

PCI is a global company that focusses on delivering speed-to-market and the commercial success of our customers

Why choose us...